Baxter International (BAX) updated its FY13 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $4.60-4.70 for the period, compared to the Thomson Reuters consensus estimate of $4.82. Baxter International also updated its Q1 guidance to $1.03-1.05 EPS.

Several analysts have also recently commented on the stock. Analysts at RBC Capital reiterated an outperform rating on shares of Baxter International in a research note to investors on Monday. They now have a $70.00 price target on the stock. On a related note, analysts at BMO Capital Markets reiterated an outperform rating on shares of Baxter International in a research note to investors on Wednesday, January 16th. They now have a $75.00 price target on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of Baxter International from $63.00 to $71.00 in a research note to investors on Friday, January 4th. They now have a hold rating on the stock.

Eight analysts have rated the stock with a buy rating, four have assigned an overweight rating, and nine have issued a hold rating to the company. The company currently has a consensus rating of overweight and a consensus price target of $71.15.

Shares of Baxter International (BAX) opened at 66.59 on Thursday. Baxter International (BAX) has a 52 week low of $48.98 and a 52 week high of $69.00. The stock’s 50-day moving average is currently $66.82. The company has a market cap of $36.583 billion and a P/E ratio of 16.23.

Baxter International last released its earnings data on Thursday, January 24th. The company reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. The company had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.72 billion. During the same quarter in the previous year, the company posted $1.17 earnings per share. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Baxter International has set its Q1 guidance at $1.03-1.05 EPS and its FY13 guidance at $4.60-4.70 EPS. Analysts expect that Baxter International (BAX) will post $4.53 EPS for the current fiscal year.

Baxter International Inc. (Baxter) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.